Accordingly, our future work will focus on formulating the 4-H1-anti-HSA-4-H1 molecule for nebulized delivery and rigorously evaluating its prophylactic and therapeutic potential in relevant respiratory infection models. This evidence concerns the gene ALB and respiratory tract infectious disorder.